intelliatx.com (NTLA): חוב לטווח קצר של החברה

This chart of Intellia Therapeutics (NTLA) stock quotes demonstrates the dynamics of a company developing cutting-edge treatments through genome modification. A team of top scientists is retained via an option system and scientific freedom. The business relies on exclusive patents and alliances with industry behemoths, which precludes price wars. The current metric stands at 0.02, while the budget is replenished by partnership payments until products reach the market.

Genetic mutation risks and CRISPR regulatory barriers create high financial uncertainty for Intellia Therapeutics (NTLA). Analyzing the history of short-term liabilities, an investor sees the total volume of obligations with a maturity date of up to one year. This metric measures current liquidity, determining the company's ability to service debt without halting expansion. A decrease in this indicator minimizes default risk but may limit development rates. The asset requires cautious monitoring of the balance between borrowing and growth.